A randomized, controlled trial of fingolimod (FTY720) in Japanese patients with multiple sclerosis.

@article{Saida2012ARC,
  title={A randomized, controlled trial of fingolimod (FTY720) in Japanese patients with multiple sclerosis.},
  author={Takahiko Saida and Seiji Kikuchi and Y. Itoyama and Q G Hao and Takayoshi Kurosawa and Kazuo Nagato and Da-ming Tang and Lixin Zhang-Auberson and Jun-ichi Kira},
  journal={Multiple sclerosis},
  year={2012},
  volume={18 9},
  pages={1269-77}
}
BACKGROUND Fingolimod (FTY720) has previously shown clinical efficacy in phase II/III studies of predominantly Caucasian populations with multiple sclerosis (MS). OBJECTIVES To report six-month efficacy and safety outcomes in Japanese patients with relapsing MS treated with fingolimod. METHODS In this double-blind, parallel-group, phase II study, 171 Japanese patients with relapsing MS were randomized to receive once-daily fingolimod 0.5 mg or 1.25 mg, or matching placebo for six months… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 2 times over the past 90 days. VIEW TWEETS

From This Paper

Topics from this paper.

Citations

Publications citing this paper.
Showing 1-10 of 19 extracted citations

Similar Papers

Loading similar papers…